Optimizing Immunotherapy in Resectable NSCLC: Adjuvant, Neoadjuvant, and Perioperative Strategies
February 26th 2025The administration of immunotherapy in adjuvant, neoadjuvant, and perioperative settings offers distinct benefits and challenges in resectable cancers, with recent clinical trials highlighting its potential to improve long-term outcomes and the need for further research into biomarkers and combination strategies.
Read More